Stock DNA
Pharmaceuticals & Biotechnology
VND 269,826 Million ()
17.00
NA
4.68%
-0.09
1.00%
0.22
Revenue and Profits:
Net Sales:
229,662 Million
(Quarterly Results - Mar 2025)
Net Profit:
-13,453 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.23%
0%
-20.23%
6 Months
3.82%
0%
3.82%
1 Year
-11.11%
0%
-11.11%
2 Years
10.57%
0%
10.57%
3 Years
-1.09%
0%
-1.09%
4 Years
-50.18%
0%
-50.18%
5 Years
0%
0%
0.0%
Mekophar Chemical Pharmaceutical JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.30%
EBIT Growth (5y)
-183.73%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
194,901.76
Tax Ratio
36.50%
Dividend Payout Ratio
30.98%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.55%
ROE (avg)
11.43%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
0.22
EV to EBIT
-3.86
EV to EBITDA
19.07
EV to Capital Employed
0.14
EV to Sales
0.17
PEG Ratio
NA
Dividend Yield
4.70%
ROCE (Latest)
-3.52%
ROE (Latest)
1.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
229,661.60
245,310.90
-6.38%
Operating Profit (PBDIT) excl Other Income
-2,928.40
30,600.40
-109.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13,452.60
14,219.70
-194.61%
Operating Profit Margin (Excl OI)
-64.00%
76.30%
-14.03%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is -6.38% vs 3.94% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is -194.61% vs 217.69% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
919,577.50
904,746.60
1.64%
Operating Profit (PBDIT) excl Other Income
38,882.00
55,542.10
-30.00%
Interest
0.00
500.90
-100.00%
Exceptional Items
0.00
17,366.80
-100.00%
Consolidate Net Profit
40,785.30
21,161.10
92.74%
Operating Profit Margin (Excl OI)
-9.30%
7.80%
-1.71%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Mekophar Chemical Pharmaceutical JSC 
Mekophar Chemical Pharmaceutical JSC
Pharmaceuticals & Biotechnology
Mekophar Chemical Pharmaceutical Joint-Stock Company (Mekophar) is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures, trades and distributes drugs, as well as chemicals and raw materials for drug manufacturing. It also manufactures and trades medical equipment and packaging, such as plastic bottles, carton boxes and paper containers. In addition, Mekophar is active in office and apartment leasing, as well as cosmetic manufacturing and trading.
Company Coordinates 
Company Details
297/5 Ly Thuong Kiet, Quan 11 , HO CHI MINH None : None
Registrar Details






